iktos in the news

Iktos combines AI and robotics to accelerate drug discovery, reducing development times and costs for new medicines.

Chemspeed Technologies and Iktos have partnered to integrate AI-orchestrated synthesis planning with robotic laboratory automation for pharmaceutical R&D.

Iktos is advancing AI-driven molecular design and robotic synthesis, recently acquiring Synsight to boost drug discovery for protein and RNA interactions.

Iktos uses AI and robotics to greatly speed up drug discovery and synthesis, collaborating with big pharma and moving its software to AWS for advanced AI integration.

Iktos and Servier have formed a €1B+ AI-driven partnership to advance oncology and neurology drug discovery.

The Artificial Intelligence Biotechnology market is growing globally with key players like Iktos driving innovation in AI-driven drug discovery and genomics, led by North America and rapidly expanding in Asia Pacific.

Iktos and Servier formed a €1B+ multi-target AI partnership to accelerate small-molecule drug discovery in oncology and neurology.

Iktos and Servier formed a €1B+ AI-driven partnership to accelerate small-molecule drug discovery in oncology and neurology.

Pierre Fabre and Iktos collaborate to accelerate oncology drug discovery using AI-driven generative design and Pierre Fabre's oncology expertise.

Iktos is advancing AI drug discovery by integrating lab data with computational methods, highlighted by a major deal with Servier.

Pierre Fabre and Iktos are collaborating to accelerate oncology drug discovery using Iktos' AI generative design platform and Pierre Fabre's oncology expertise.

Iktos and Servier are collaborating on a multi-target AI partnership valued over €1 billion to accelerate drug discovery in oncology and neurology.

Iktos and Servier have entered a €1B+ partnership using AI-driven molecular design to develop new drugs for oncology and neurology.

Pierre Fabre Laboratories and Iktos are collaborating to discover and develop new oncology drug candidates using AI.

Pierre Fabre Laboratories and Iktos announced a collaboration to discover and develop new small-molecule drug candidates for oncology using AI and preclinical development.

Iktos and Servier entered a multi-year, multi-target AI partnership, potentially worth over –1 billion, to accelerate small-molecule drug discovery in oncology and neurology.

Iktos and Servier formed a €1B+ multi-target AI partnership to accelerate small-molecule drug discovery in oncology and neurology.

Iktos and Servier formed a €1 billion+ multi-year collaboration using AI to accelerate small molecule drug discovery in oncology and neurology.

Pierre Fabre Laboratories and Iktos partnered to use AI for discovering small-molecule cancer drug candidates.

Iktos partnered with Servier in a one billion euro deal to develop oncology and neurology drugs.